Study assessments
Cancer
ADVERSE EVENT, ADVERSE EVENT, MYELOMA, CANCER
Hematology and biochemistry tests were done at baseline, before each plitidepsin or BTZ administration during Cycle 1, and before each plitidepsin administration during subsequent cycles.Adverse events (AEs) and laboratory abnormalities were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI‐CTCAE) v.4. Antitumor activity was evaluated according to the International Myeloma Working Group (IMWG) criteria.